# 29th-31st Scientific Conference Society on NeuroImmune Pharmacology

> **NIH DA R13** · SOCIETY ON NEUROIMMUNE PHARMACOLOGY · 2026 · $35,000

## Abstract

The Society on Neuroimmune Pharmacology (SNIP) scientific meetings are focused on uncovering how substance abuse renders humans more susceptible to infection and chronic diseases, with a particular focus on human immunodeficiency virus-1 (HIV-1). It is the only conference in the US and worldwide devoted to neuroimmune pharmacology, and the neuroimmune axis as it relates to drug abuse, inflammation and brain infections (primarily neuroHIV). SNIP has been previously supported by R13s DA0123184 and DA046315.
Our programs feature several seminal presentations never before included in the Society’s agenda. These include plenary speakers, each with unique and significant contributions to their fields, world-famous physician scientists and several luminaries. Keynote and memorial lectures are from leaders in the field who have made groundbreaking contributions including the discovery of vital cellular mechanisms, novel therapeutic compounds and elucidating underlying pathological agents. Expertise includes virology, neurodegenerative diseases pathobiology and therapies, immunology and addiction research. In addition to our keynote and memorial
lectures, we have included topics such as community engagement, addiction management and personal accounts about taking care of people that are impacted by these devastating illnesses. These unique seminars provide rich depth regarding the experiences of people with addiction, HIV, and neurological conditions. Every SNIP annual meeting includes symposiums submitted by the membership centered around current and future novel topics of the field. Our line-up includes experts from industry, pharmaceuticals, academic institutes, and independent scientific institutes. These topics highlight the latest technological advances, new treatments and drug formulations, novel diagnostics methodologies, bioinformatics, AI and OMICS advancements, basic and
clinical findings. Moreover, several topics highlight aspects of addiction that are unique to 

## Key facts

- **NIH application ID:** 11387804
- **Project number:** 5R13DA063455-02
- **Recipient organization:** SOCIETY ON NEUROIMMUNE PHARMACOLOGY
- **Principal Investigator:** Allison Michelle Andrews; Howard E Gendelman; Sabita  Roy
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** DA
- **Fiscal year:** 2026
- **Award amount:** $35,000
- **Award type:** 5
- **Project period:** 2025-08-01T00:00:00 → 2028-03-31T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11387804

## Citation

> US National Institutes of Health, RePORTER application 11387804, 29th-31st Scientific Conference Society on NeuroImmune Pharmacology (5R13DA063455-02). Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/grant/nih/11387804. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*